PTN Stock Analysis: Buy, Sell, or Hold?
$8.85
-0.67 (-7.04%)
▼
5d:
-19.47%
30d:
-35.31%
90d:
-52.19%
WAIT
LOW Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 12, 2026
28d
Get Alerted When PTN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PTN is down 19.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PTN is down 19.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PTN is currently trading at $8.85, which is considered oversold relative to its 30-day fair value range of $10.08 to $13.08.
Technical Outlook: Technically, PTN is in a downtrend. The price is currently testing key support at $13.09. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.0% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $53.50 (+504.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PTN is in a downtrend. The price is currently testing key support at $13.09. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.0% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $53.50 (+504.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$10.08 -
$13.08
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.0%)
- BULLISH: Trading 504.5% below Wall St target ($53.50)
- WARNING: Recommendation downgraded due to -19.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$10.08 -
$13.08
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$13.09
Resistance Level
$14.88
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.64
Wall Street Target
$53.50
(+504.5%)
Revenue Growth (YoY)
-80.1%
Profit Margin
-48.5%
Share & Embed Analysis
Last updated: July 14, 2026 5:54 PM ET
Data refreshes hourly during market hours. Next update: 6:54 PM
Data refreshes hourly during market hours. Next update: 6:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PTN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 51 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 55 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 62 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 62 BUY |